**REFERENCES**

**Medical consensus papers**

Garden, O.A., Kidd, L., Mexas, A.M., Chang, Y.M., Jeffery, U., Blois, S.L., Fogle, J.E., MacNeill, A.L., Lubas, G., Birkenheuer, A. and Buoncompagni, S., 2019. ACVIM consensus statement on the diagnosis of immune‐mediated hemolytic anemia in dogs and cats. *Journal of veterinary internal medicine*, *33*(2), pp.313-334. Link: <https://pubmed.ncbi.nlm.nih.gov/30806491/>

IRIS Canine GN Study Group Established Pathology Subgroup, Segev, G., Cowgill, L.D., Heiene, R., Labato, M.A. and Polzin, D.J., 2013. Consensus recommendations for immunosuppressive treatment of dogs with glomerular disease based on established pathology. *Journal of veterinary internal medicine*, *27*, pp.S44-S54. Link: <https://pubmed.ncbi.nlm.nih.gov/24635379/>

IRIS Canine GN Study Subgroup on Immunosuppressive Therapy Absent a Pathologic Diagnosis, Pressler, B., Vaden, S., Gerber, B., Langston, C. and Polzin, D., 2013. Consensus guidelines for immunosuppressive treatment of dogs with glomerular disease absent a pathologic diagnosis. *Journal of veterinary internal medicine*, *27*, pp.S55-S59.. Link: <https://pubmed.ncbi.nlm.nih.gov/24635381/>

Swann, J.W., Garden, O.A., Fellman, C.L., Glanemann, B., Goggs, R., LeVine, D.N., Mackin, A.J. and Whitley, N.T., 2019. ACVIM consensus statement on the treatment of immune‐mediated hemolytic anemia in dogs. *Journal of veterinary internal medicine*, *33*(3), pp.1141-1172. Link: <https://pubmed.ncbi.nlm.nih.gov/30847984/>

Webster, C.R., Center, S.A., Cullen, J.M., Penninck, D.G., Richter, K.P., Twedt, D.C. and Watson, P.J., 2019. ACVIM consensus statement on the diagnosis and treatment of chronic hepatitis in dogs. *Journal of veterinary internal medicine*, *33*(3), pp.1173-1200. Link: <https://onlinelibrary.wiley.com/doi/10.1111/jvim.15467>

**Review on immunosuppressives**

Viviano, K.R., 2013. Update on immununosuppressive therapies for dogs and cats. *Veterinary Clinics: Small Animal Practice*, *43*(5), pp.1149-1170.. <https://www.vetsmall.theclinics.com/article/S0195-5616(13)00114-9/pdf>

**Dermatology references**

Ackermann, A.L., May, E.R. and Frank, L.A., 2017. Use of mycophenolate mofetil to treat immune‐mediated skin disease in 14 dogs–a retrospective evaluation. *Veterinary dermatology*, *28*(2), pp.195-e44. <https://doi.org/10.1111/vde.12400>

Bizikova, P. and Olivry, T., 2015. Oral glucocorticoid pulse therapy for induction of treatment of canine pemphigus foliaceus–a comparative study. *Veterinary dermatology*, *26*(5), pp.354-e77.

<https://www.researchgate.net/profile/Thierry-Olivry/publication/280869719_Oral_glucocorticoid_pulse_therapy_for_induction_of_treatment_of_canine_pemphigus_foliaceus_-_a_comparative_study/links/56bf35bf08ae2f498ef7e5f2/Oral-glucocorticoid-pulse-therapy-for-induction-of-treatment-of-canine-pemphigus-foliaceus-a-comparative-study.pdf>

Banovic, F., Tarigo, J., Gordon, H., Barber, J.P. and Gogal Jr, R.M., 2019. Immunomodulatory in vitro effects of oclacitinib on canine T‐cell proliferation and cytokine production. *Veterinary dermatology*, *30*(1), pp.17-e6. <https://onlinelibrary.wiley.com/doi/abs/10.1111/vde.12698>

Byrne, K. and Morris, D.O., 2001. Study to determine the usefulness of Mycophenolate mofetil (MMF) for the treatment of pemphigus foliaceus in the dog. *American Academy of Veterinary Dermatology Proceedings*.

Didona, D., Maglie, R., Eming, R. and Hertl, M., 2019. Pemphigus: current and future therapeutic strategies. *Frontiers in immunology*, *10*, p.1418. <https://www.frontiersin.org/articles/10.3389/fimmu.2019.01418/full>

Ferrigno, A., Hoover, K., Blubaugh, A., Rissi, D. and Banovic, F., 2019. Treatment of exfoliative cutaneous lupus erythematosus in a German shorthaired pointer dog with mycophenolate mofetil. *Veterinary dermatology*, *30*(4), pp.350-e102.

Gray, L.L., Hillier, A., Cole, L.K. and Rajala‐Schultz, P.J., 2013. The effect of ketoconazole on whole blood and skin ciclosporin concentrations in dogs. *Veterinary Dermatology*, *24*(1), pp.118-e28. <https://www.researchgate.net/profile/Thierry-Olivry/publication/280869719_Oral_glucocorticoid_pulse_therapy_for_induction_of_treatment_of_canine_pemphigus_foliaceus_-_a_comparative_study/links/56bf35bf08ae2f498ef7e5f2/Oral-glucocorticoid-pulse-therapy-for-induction-of-treatment-of-canine-pemphigus-foliaceus-a-comparative-study.pdf>

Jasiecka-Mikołajczyk, A., Jaroszewski, J.J. and Maślanka, T., 2018. Oclacitinib depletes canine CD4+ and CD8+ T cells in vitro. *Research in veterinary science*, *121*, pp.124-129. <https://www.sciencedirect.com/science/article/pii/S0034528818313250>

Kidd, L.B., Salavaggione, O.E., Szumlanski, C.L., Miller, J.L., Weinshilboum, R.M. and Trepanier, L., 2004. Thiopurine methyltransferase activity in red blood cells of dogs. *Journal of veterinary internal medicine*, *18*(2), pp.214-218. <https://onlinelibrary.wiley.com/doi/pdf/10.1111/j.1939-1676.2004.tb00163.x>

Oberkirchner, U., Linder, K.E. and Olivry, T., 2012. Successful treatment of a novel generalized variant of canine discoid lupus erythematosus with oral hydroxychloroquine. *Veterinary dermatology*, *23*(1), pp.65-e16. <https://doi.org/10.1111/j.1365-3164.2011.00994.x>

Mauldin, E.A., Morris, D.O., Brown, D.C. and Casal, M.L., 2010. Exfoliative cutaneous lupus erythematosus in German shorthaired pointer dogs: disease development, progression and evaluation of three immunomodulatory drugs (ciclosporin, hydroxychloroquine, and adalimumab) in a controlled environment. *Veterinary dermatology*, *21*(4), pp.373-382. <https://doi.org/10.1111/j.1365-3164.2010.00867.x>